Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Democratic Capitol Hill Will Create Challenges For Brand Industry

Executive Summary

The sweep of both houses of Congress in the midterm elections will allow the Democrats the opportunity to push their agenda through must-pass legislation such as the reauthorization of the Prescription Drug User Fee Act

You may also be interested in...



Rx Importation Legislation Debate Begins Anew, But Battle Lines Are Familiar

Sens. Byron Dorgan, D-S.D., and Olympia Snowe, R-Maine, are trying to build momentum for their proposal to allow prescription drug importation, vowing at a March 7 hearing that they will push to bring the measure quickly to the Senate floor

Rx Importation Legislation Debate Begins Anew, But Battle Lines Are Familiar

Sens. Byron Dorgan, D-S.D., and Olympia Snowe, R-Maine, are trying to build momentum for their proposal to allow prescription drug importation, vowing at a March 7 hearing that they will push to bring the measure quickly to the Senate floor

BIO lawyers up

The Biotechnology Industry Organization appoints Sandra Dennis to the newly created position of Deputy General Counsel for Healthcare Regulatory Affairs. The addition of Dennis serves to "enhance BIO's advocacy for a regulatory environment that allows biotechnology industry to bring ... technologies to market," BIO President Jim Greenwood says in a Jan. 9 release. The trade association is bolstering its regulatory affairs department at a time many anticipate increased Congressional interest in the establishment of a regulatory framework for approval of generic biologics (1"The Pink Sheet" Nov. 13, 2006, p. 3). Dennis comes to BIO from Morgan, Lewis & Bockius' FDA/Healthcare Regulation practice group, where she focused on regulatory, legislative, policy and corporate issues...

Related Content

UsernamePublicRestriction

Register

ID014775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel